Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 62INDUSTRY 7OTHER_GOV 2NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Mouth Neoplasms 1Leukoplakia, Oral 1Hyperplasia 1Erythroplasia 1

Interventions

Specimen Handling 354Magnetic Resonance Spectroscopy 252Biopsy 222Nivolumab 69Cyclophosphamide 65Carboplatin 56Radiation 53Paclitaxel 53X-Rays 52pembrolizumab 51Taxes 51Immunoglobulin G 51Disulfides 51Cisplatin 49Platinum 451,2-diaminocyclohexaneplatinum II citrate 45Doxorubicin 44Radiotherapy 42Ipilimumab 38atezolizumab 37fludarabine 35Gemcitabine 35CTLA-4 Antigen 35olaparib 32Vincristine 31Prednisone 31Bevacizumab 30venetoclax 27Cytarabine 27Phantoms, Imaging 26

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Metformin × 1 year × Clear all
NCT02581137 2026-04-13

Metformin Hydrochloride in Preventing Oral Cancer in Patients With an Oral Premalignant Lesion

National Cancer Institute (NCI)

Phase 2 Active not recruiting
26 enrolled 10 charts
Head & Neck

Erythroplasia, Hyperplasia, Leukoplakia, Oral, Mouth Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡